| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.82▼ | 0.82▼ | 0.82▼ | 0.86▼ | 0.83▼ |
| MA10 | 0.83▼ | 0.83▼ | 0.85▼ | 0.89▼ | 0.80▲ |
| MA20 | 0.86▼ | 0.88▼ | 0.89▼ | 0.86▼ | 0.72▲ |
| MA50 | 0.88▼ | 0.89▼ | 0.88▼ | 0.79▲ | 0.79▲ |
| MA100 | 0.90▼ | 0.84▼ | 0.83▼ | 0.71▲ | 1.14▼ |
| MA200 | 0.84▼ | 0.81▲ | 0.79▲ | 0.77▲ | 1.68▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.003▼ | -0.009▼ | -0.013▼ | -0.010▼ | 0.027▲ |
| RSI | 26.886▼ | 28.138▼ | 31.267▼ | 46.376▼ | 52.317▲ |
| STOCH | 3.441▼ | 0.168▼ | 0.000▼ | 30.587 | 69.093 |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -98.173▼ | -38.174 |
| CCI | -121.472▼ | -78.025 | -88.685 | -236.885▼ | 101.893▲ |
|
Thursday, March 26, 2026 10:56 PM
On September 2025, SCYNEXIS announced positive Phase 1 SAD/MAD results for the oral formulation of its second-generation fungerp, SCY-247, demonstrating good tolerability, favorable pharmacokinetics, ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 27/03/26 | 0.84 | 0.84 | 0.8102 | 0.8129 | 144,435 |
| 26/03/26 | 0.8321 | 0.8694 | 0.82 | 0.8375 | 112,083 |
| 25/03/26 | 0.90 | 0.949 | 0.8802 | 0.8808 | 31,052 |
| 24/03/26 | 0.89 | 0.9038 | 0.865 | 0.90 | 122,297 |
| 23/03/26 | 0.9323 | 0.95 | 0.8711 | 0.8755 | 271,359 |
| 20/03/26 | 0.91 | 0.9411 | 0.8833 | 0.9323 | 332,200 |
| 19/03/26 | 0.90 | 0.92 | 0.8842 | 0.894 | 86,827 |
| 18/03/26 | 0.9205 | 0.9247 | 0.8811 | 0.8998 | 133,663 |
| 17/03/26 | 0.918 | 0.941 | 0.899 | 0.9205 | 178,874 |
| 16/03/26 | 0.87 | 0.958 | 0.8591 | 0.899 | 418,268 |
|
|
||||
|
|
||||
|
|